secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2026-07-01T20:13:51+00:00
Accession:  0001501697-26-000060
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals appoints Kelly Gold to Board of Directors
------------------------------------------------------------

- Kelly Gold appointed as Class II director effective July 1, 2026; board expands from 5 to 6 members.
- Gold is CFO of CAMP4 Therapeutics (Nasdaq: CAMP) and will serve on Audit Committee.
- Gold brings financial leadership, capital markets expertise, and rare disease experience from Biogen.
- No arrangements or family relationships with other directors/officers; standard compensation per non-employee director policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000060/0001501697-26-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000060/xfor-20260630.htm
  HTML page:      https://secwatch.observer/filing/0001501697-26-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer